We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

35 hedge funds and large institutions have $109M invested in Monopar Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,700% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 1

94% more funds holding

Funds holding: 18 → 35 (+17)

91% more capital invested

Capital invested by funds: $57.1M → $109M (+$52.2M)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

4.91% more ownership

Funds ownership: 42.41% → 47.31% (+4.9%)

Holders
35
Holders Change
+17
Holders Change %
+94.44%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
6
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.15M
2
AAA
Affinity Asset Advisors
New York
+$2.23M
3
Millennium Management
Millennium Management
New York
+$2.18M
4
Marshall Wace
Marshall Wace
United Kingdom
+$936K
5
Goldman Sachs
Goldman Sachs
New York
+$666K

Top Sellers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
-$1.05M
2
Morgan Stanley
Morgan Stanley
New York
-$85.7K
3
JP Morgan Chase
JP Morgan Chase
New York
-$69.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$45.9K
5
TRCT
Tower Research Capital (TRC)
New York
-$14.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$45.6M +$3.15M +87,507 +8%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$21.8M – – –
RCM
3
RA Capital Management
Massachusetts
$18.6M – – –
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$6.12M +$9.66K +268 +0.2%
ACM
5
ADAR1 Capital Management
Texas
$3.67M -$1.05M -29,263 -23%
AAA
6
Affinity Asset Advisors
New York
$2.26M +$2.23M +62,000 New
Millennium Management
7
Millennium Management
New York
$2.2M +$2.18M +60,367 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$2.01M -$45.9K -1,275 -2%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.77M +$358K +9,944 +26%
Marshall Wace
10
Marshall Wace
United Kingdom
$946K +$936K +25,988 New
Goldman Sachs
11
Goldman Sachs
New York
$673K +$666K +18,480 New
State Street
12
State Street
Massachusetts
$576K +$570K +15,814 New
BlackRock
13
BlackRock
New York
$527K +$229K +6,363 +79%
Jane Street
14
Jane Street
New York
$377K +$373K +10,357 New
Northern Trust
15
Northern Trust
Illinois
$334K +$330K +9,161 New
OAC
16
OMERS Administration Corp
Ontario, Canada
$328K +$324K +9,000 New
HF
17
HRT Financial
New York
$299K +$296K +8,228 New
UBS Group
18
UBS Group
Switzerland
$296K +$61.2K +1,698 +26%
Balyasny Asset Management
19
Balyasny Asset Management
Illinois
$224K +$221K +6,141 New
IC
20
Ikarian Capital
Texas
$215K – – –
GL
21
Gerber LLC
Ohio
$204K +$202K +5,601 New
Bank of America
22
Bank of America
North Carolina
$90.2K +$88.3K +2,450 +8,750%
PAS
23
Point72 Asia (Singapore)
Singapore
$64.1K +$63.5K +1,761 New
Morgan Stanley
24
Morgan Stanley
New York
$51.8K -$85.7K -2,377 -63%
A
25
AlphaQuest
New York
$44.2K +$43.8K +1,215 New
1
2

MNPR Hedge Fund Activity: Q1 2025 in Review

35 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2025, worth a combined $109M — up 91% from $57.1M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new MNPR positions and 1 closed out — a net gain of 17 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $3.15M. The largest seller was ADAR1 Capital Management, cutting an estimated $1.05M.

  • 35 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2025, up from 18 in Q4 2024.
  • Funds reported $109M of Monopar Therapeutics stock for Q1 2025, up 91% quarter-over-quarter.
  • 18 funds opened new Monopar Therapeutics positions in Q1 2025 and 1 closed out, a net change of +17 holders.
  • The largest Monopar Therapeutics buyer in Q1 2025 was Janus Henderson Group, an estimated $3.15M added.
  • The largest Monopar Therapeutics seller in Q1 2025 was ADAR1 Capital Management, an estimated $1.05M sold.

Based on aggregated 13F filings for Q1 2025.